Impact of a patient’s gut microbiome on clinical response to cancer immunotherapy

Chair: Trevor Lawley, Wellcome Trust Sanger Institute
Speaker: Robert Jenq, MD Anderson Cancer Center, USA
Speaker: Trevor Lawley, Wellcome Trust Sanger Institute, UK
Speaker: Paul O'Toole, University College Cork, Ireland


Room: Lomond Auditorium

The bacteria present in a patients intestinal microbiota can impact the clinical response to cancer immunotherapies. These observations raise the possibility to identify biomarkers predictive of treatment response, resistance and toxicity, and potentially to manipulate the patients microbiome prior to treatment to optimize cancer therapy. The proposed speakers will discuss recent advances in this area, including clinical studies and pre-clinical experimentation, and future prospects to improve cancer therapy. Given the high profile of this area the session will be of interest of broad interest to both basic and clinical scientists.